No Data
No Data
Digel Pharmaceuticals: 2024 Semi-Annual Report
Digel Pharmaceuticals: 2024 Semi-Annual Report Summary
Di Zhe Pharmaceuticals (688192.SH): net loss of 0.345 billion yuan in the first half of the year.
On August 29th, Dezhe Medicine (688192.SH) released its 2024 semi-annual report, with the company's revenue for the reporting period at 0.204 billion yuan; the net loss attributable to shareholders of the listed company narrowed to 0.345 billion yuan; the net loss attributable to shareholders of the listed company after deducting non-recurring gains and losses narrowed to 0.381 billion yuan; the basic loss per share was 0.83 yuan/share.
Dizhe Pharmaceuticals (688192.SH) released its performance for the first half of the year, with a net loss of 0.345 billion yuan, narrowing the loss.
Di Zhe Pharmaceutical (688192.SH) released its semi-annual report for 2024, with revenue of 0.204 billion yuan...
Di Zhe Pharmaceuticals achieved revenue of over 0.2 billion yuan in the first half of the year, with high sequential growth for three consecutive quarters.
Shanghai, August 29, 2024 / PRNewswire / - On August 29, 2024, Dizz Medicine announced its mid-year report for 2024. With the rapid increase in sales of its core product, Shuwotini, it achieved a total revenue of 0.204 billion yuan in the first half of the year, and the net loss attributable to shareholders of the parent company decreased for three consecutive quarters, a decrease of 33% compared to the same period last year. In the first half of this year, with the gradual realization of research and development results and the income growth brought by commercialization, Dizz Medicine's innovative logic of "Research and Development-Commercialization-Research and Development" began to be realized, and the company's financial data gradually started to move towards a positive cycle, persistently pursuing the value of original innovation.
Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Weighed On By Its Debt Load?
No Data